Nuritas Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nuritas Ltd. - overview
Established
2014
Location
Dublin, -, Ireland
Primary Industry
Biotechnology
About
Based in Ireland, Nuritas Ltd. specializes in biotechnology by developing cell-signaling peptides derived from natural sources to enhance health and wellness across various industries. Nuritas Ltd. , founded in 2014, is headquartered in Dublin, Ireland.
The company focuses on biotechnology, specifically developing bioactive peptides for dietary supplements and cosmetics. Nora K is the CEO and founder, who has a background in health sciences. Nuritas has completed a total of 10 funding deals, with the most recent being a SERIES C round on December 20, 2024, where they raised USD 42. 00 mn led by M&G Investments and supported by investors like ECBF Management GmbH, Grosvenor, and McWin.
The total amount raised by the company stands at USD 42. 00 mn. Nuritas specializes in precision, cell-signaling peptide ingredients sourced from natural materials. Their leading products, PeptiYouth™ and PeptiStrong™, enhance the effectiveness of dietary supplements, functional foods, medical foods, and cosmetics.
Utilizing advanced AI technology, Nuritas identifies and unlocks bioactive peptides, with a library cataloging over 8 million peptides, each with specific functionalities. The company primarily markets its products in North America, Europe, and Asia, serving a broad client base that includes manufacturers and health-conscious consumers. In the most recent year, Nuritas reported a revenue of USD 1,172,928. 70.
The company generates income through partnerships in the health, nutrition, and cosmetics sectors, supplying proprietary peptide ingredients such as PeptiYouth™ and PeptiStrong™ to manufacturers. Their business model includes collaboration agreements and licensing fees tailored to meet the specific needs of clients, ensuring competitive pricing while maintaining product integrity. In December 2024, Nuritas, Ltd. raised USD 42.
00 mn in SERIES C funding, led by M&G Investments, to further develop its AI platform for discovering and creating a range of holistic products. This funding will support the launch of new products targeting health and wellness challenges, aiming for market expansion into additional regions within Europe and Asia by 2025.
Current Investors
European Union, Cultivian Sandbox Ventures, Clay Capital
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Commodity Chemicals
Website
www.nuritas.com/
Verticals
Artificial Intelligence, Big Data
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.